In a phase 3 clinical trial, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

An investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron (Eli Lilly), demonstrated superior ...

Orforglipron carried more side effects, however ...

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial ...

PHOENIX, AZ - February 27, 2026 - PRESSADVANTAGE - Phoenix NP, a women-focused telehealth medical practice based in ...

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had ...

The findings add to competitive pressure on Novo Nordisk’s GLP-1 portfolio and come days after the Danish drugmaker reported ...

Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), ...

Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in ...